Evidence map›Paper›PMID 27471650›Full record

ArticleOncoimmunology2016

IL-7 signaling imparts polyfunctionality and stemness potential to CD4(+) T cells.

Zhi-Chun Ding, Chufeng Liu, Yang Cao, Tsadik Habtetsion, Michal Kuczma, Wenhu Pi, Heng Kong, Ercan Cacan, Susanna F Greer, Yan Cui and 3 more

Open access · goldAbstract read
In one paragraph

Article in Oncoimmunology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Improving CAR T-Cell Persistence.International journal of molecular sciences · 2021
    Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 7 institutions in 2 countries.

Zhi-Chun DingCancer Immunology, Inflammation and Tolerance Program, Georgia Cancer Center, Augusta University , Augusta, GA, USA.
Chufeng LiuCancer Immunology, Inflammation and Tolerance Program, Georgia Cancer Center, Augusta University, Augusta, GA, USA; Department of Orthodontics, Guangdong Provincial Stomatological Hospital, Southern Medical University, Guangzhou, PR, China.
Yang CaoCancer Immunology, Inflammation and Tolerance Program, Georgia Cancer Center, Augusta University, Augusta, GA, USA; Department of Orthodontics, Guangdong Provincial Key Laboratory of Stomatology, Hospital of Stomatology, Sun Yat-sen University, Guangzhou, PR, China.
Tsadik HabtetsionCancer Immunology, Inflammation and Tolerance Program, Georgia Cancer Center, Augusta University , Augusta, GA, USA.
Michal KuczmaCancer Immunology, Inflammation and Tolerance Program, Georgia Cancer Center, Augusta University , Augusta, GA, USA.
Wenhu PiDepartment of Biochemistry and Molecular Biology, Augusta University , Augusta, GA, USA.
Heng KongCancer Immunology, Inflammation and Tolerance Program, Georgia Cancer Center, Augusta University, Augusta, GA, USA; Department of Thyroid and Breast Surgery, Shenzhen Nanshan District People's Hospital, Shenzhen, Guangzhou, PR, China.
Ercan CacanDepartment of Biology, Georgia State University , Atlanta, GA, USA.
Susanna F GreerDepartment of Biology, Georgia State University , Atlanta, GA, USA.
Yan CuiCancer Immunology, Inflammation and Tolerance Program, Georgia Cancer Center, Augusta University , Augusta, GA, USA.
Bruce R BlazarDepartment of Pediatrics and Division of Blood and Marrow Transplantation, University of Minnesota , Minneapolis, MN, USA.
David H MunnCancer Immunology, Inflammation and Tolerance Program, Georgia Cancer Center, Augusta University , Augusta, GA, USA.
Gang ZhouCancer Immunology, Inflammation and Tolerance Program, Georgia Cancer Center, Augusta University , Augusta, GA, USA.
Augusta University Health · USGeorgia State University · USAugusta University · USShenzhen Sixth People's Hospital · CNSouthern Medical University · CNStomatology Hospital · CNUniversity of Minnesota · US

Funding

Reprogramming the TME for immunogenic antigen-presentationR01CA103320 · NCI · MEDICAL COLLEGE OF GEORGIA (MCG) · PI MUNN, DAVID H. · 2003 to 2024
$6.0M
GVL TO REDUCE AML RELAPSE AFTER MURINE ALLOGENEIC BMTR01CA072669 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI BLAZAR, BRUCE R · 1997 to 2017
$4.9M
Role of IDO malignancyR01CA096651 · NCI · MEDICAL COLLEGE OF GEORGIA (MCG) · PI MUNN, DAVID H. · 2003 to 2016
$3.3M
P53 inactivation on MDSC development and tumor progressionR01CA169133 · NCI · LSU HEALTH SCIENCES CENTER · PI CUI, YAN · 2013 to 2017
$1.5M
Reversing tumor-specific CD4+ T-cell tolerance to control relapse after chemotherR01CA158202 · NCI · AUGUSTA UNIVERSITY · PI ZHOU, GANG · 2012 to 2016
$1.4M
NCI NIH HHS R01 CA072669NCI NIH HHS R01 CA096651NCI NIH HHS R01 CA103320NCI NIH HHS R01 CA158202NCI NIH HHS R01 CA169133
6 · The paper itself

Abstract

The functional status of CD4(+) T cells is a critical determinant of antitumor immunity. Polyfunctional CD4(+) T cells possess the ability to concomitantly produce multiple Th1-type cytokines, exhibiting a functional attribute desirable for cancer immunotherapy. However, the mechanisms by which these cells are induced are neither defined nor it is clear if these cells can be used therapeutically to treat cancer. Here, we report that CD4(+) T cells exposed to exogenous IL-7 during antigenic stimulation can acquire a polyfunctional phenotype, characterized by their ability to simultaneously express IFNγ, IL-2, TNFα and granzyme B. This IL-7-driven polyfunctional phenotype was associated with increased histone acetylation in the promoters of the effector genes, indicative of increased chromatin accessibility. Moreover, forced expression of a constitutively active (CA) form of STAT5 recapitulated IL-7 in inducing CD4(+) T-cell polyfunctionality. Conversely, the expression of a dominant negative (DN) form of STAT5 abolished the ability of IL-7 to induce polyfunctional CD4(+) T cells. These in-vitro-generated polyfunctional CD4(+) T cells can traffic to tumor and expand intratumorally in response to immunization. Importantly, adoptive transfer of polyfunctional CD4(+) T cells following lymphodepletive chemotherapy was able to eradicate large established tumors. This beneficial outcome was associated with the occurrence of antigen epitope spreading, activation of the endogenous CD8(+) T cells and persistence of donor CD4(+) T cells exhibiting memory stem cell attributes. These findings indicate that IL-7 signaling can impart polyfunctionality and stemness potential to CD4(+) T cells, revealing a previously unknown property of IL-7 that can be exploited in adoptive T-cell immunotherapy.

Indexed as

Adoptive cell therapyCD4+IL-7polyfunctionalT memory stem cell

Identifiers

PMID27471650
PMCPMC4938319
OpenAlexW2344961767

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.